文献速递淋巴瘤浆细胞疾病

ACCELERATE登记中结局致命的Castleman病患者疾病病程

The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
PubMed 文献 · Br J Haematol · 2022-05-04

该研究分析ACCELERATE登记中所有已故Castleman病(CD)患者,并与匹配对照及特发性多中心Castleman病(iMCD)亚组比较。140例确诊CD中10例死亡,72例确诊iMCD中6例死亡。已故CD队列每年住院次数、总住院次数、每月住院天数及每年治疗方案数均多于匹配对照,第3、6个月绝对淋巴细胞计数显著降低;已故iMCD组iMCD-TAFRO比例更高,免疫球蛋白M、国际标准化比值和血小板计数显著更低。

要点

  • 已故CD患者每年住院次数、总住院次数、每月住院天数及每年治疗方案数均多于匹配对照。
  • 已故CD队列第3、6个月绝对淋巴细胞计数较对照显著降低。
  • 已故iMCD组iMCD-TAFRO比例更高,免疫球蛋白M、国际标准化比值和血小板计数显著更低。

核心结论

  • 这些数据表明,致命结局与非致命结局的Castleman病患者之间可能存在差异,并为需进一步评估的参数提供初步建议。

研究设计与样本

  • 分析ACCELERATE登记中所有已故Castleman病(CD)患者的数据,并与匹配对照及特发性多中心Castleman病(iMCD)患者亚组进行比较。
  • ACCELERATE登记中140例确诊CD患者中10例死亡;72例确诊iMCD患者中6例死亡。

主要发现

  • 已故CD队列每年住院次数、总住院次数、每月住院天数及每年接受的治疗方案数均多于匹配对照组。
  • 已故CD队列第3个月和第6个月绝对淋巴细胞计数较对照显著降低。
  • 已故iMCD组中iMCD-TAFRO(血小板减少、全身水肿、发热、网状纤维骨髓纤维化、肾功能不全和器官肿大)病例比例高于对照组。
  • 已故iMCD组免疫球蛋白M、国际标准化比值和血小板计数显著低于对照组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Castleman disease (CD) describes a group of rare, potentially fatal lymphoproliferative disorders. To determine factors associated with mortality in CD, we analysed data from deceased patients in the ACCELERATE registry and compared them with matched controls. We analysed demographic, treatment and laboratory data from all deceased CD patients, matched controls and a subgroup of idiopathic multicentric Castleman disease (iMCD) patients. Of the 140 patients in ACCELERATE with a confirmed CD diagnosis, 10 had died. There were 72 patients with confirmed iMCD; six were deceased. The deceased CD cohort had more hospitalisations per year, higher overall hospitalisations and more days hospitalised per month, and received more treatment regimens per year than the matched-control group. Analysis of laboratory values showed a significantly decreased absolute lymphocyte count at months 3 and 6 in the deceased cohort compared with controls. Among iMCD patients, there was a higher proportion of iMCD-TAFRO (thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction and organomegaly) cases in the deceased group. The deceased iMCD group had significantly lower immunoglobulin M, international normalised ratio and platelet count. These data demonstrate that there may be differences between patients who have fatal and non-fatal outcomes, and provide preliminary suggestions for parameters to evaluate further.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Fajgenbaum DC, Pierson SK, Kanhai K, et al. The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry. Br J Haematol. 2022. PMID: 35507638. doi:10.1111/bjh.18214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。